首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1623504

2024 年至 2031 年血型檢測市場（按產品類型、檢測類型、最終用戶和地區劃分）

Blood Group Typing Market By Product, Test Type, Technique, End-User, Region for 2024-2031

出版日期: 2024年10月31日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

血型鑑定市場評估，2024 年至 2031 年

自願捐血量的增加促使對血型辨識和輸血交叉配血程序的需求增加。因此，自願捐血數量的增加推動了市場規模的激增，到 2024 年將超過 29.6 億美元，到 2031 年將達到 61.6 億美元的估值。

癌症、血液疾病和慢性貧血等疾病的發生率不斷上升，推動了輸血的需求，因此也推動了血型鑑定的需求。因此，由於需要輸血的慢性病發生率不斷上升，市場將從 2024 年到 2031 年的複合年增長率達到 9.60%。

血型鑑定市場定義/概論

血型鑑定是一項重要的醫療程序，透過識別紅血球表面的某些抗原來確定一個人的血型。這個過程用於各種醫療程序，例如確保輸血和器官移植的兼容性，以及管理妊娠以防止新生兒溶血性疾病（當母親的免疫系統攻擊胎兒的紅血球時發生）。重要。

由於輸血和器官移植的需求不斷增加，對準確血型的需求也不斷增加。根據世界衛生組織（WHO）的報告，自願捐血人數大幅增加，2008年至2018年間捐血次數增加了1070萬次，血型鑑定數量也相應增加。世界各地事故、創傷和傷害數量的增加進一步推動了這種需求的成長。研究表明，每 10 例創傷死亡病例中，就有 6 例是由於最初 3 小時內失血過多造成的，這凸顯了及時輸血（需要準確進行血型鑑定）的重要性。

基因檢測和分子診斷的進步正在提高血型檢測的準確性和速度，為更精準、個人化的醫療保健解決方案鋪平了道路。隨著醫療保健系統優先考慮患者安全和個人化治療，對可靠血型的需求預計將增長，從而推動醫療保健應用的進一步擴展。

血型檢測方法的技術進步將如何推動血型檢測市場的成長？

血型技術的創新，例如分子分型和自動化系統，提高了血型測試的效率和準確性。根據《輸血醫學評論》雜誌 2020 年發表的一項研究，2015 年至 2019 年間，血庫中自動血型分型系統的採用率增加了 35%。醫療保健提供者和患者對準確血型重要性的認識不斷提高，推動了市場的成長。 2018 年，負責認證美國醫療機構的聯合委員會報告稱，實施包括嚴格的輸血前檢測在內的患者血液管理計劃，使參與計劃的醫院的血液製品使用量平均減少了 12%。

外科手術數量的增加（其中許多需要輸血）推動了對血型鑑定的需求。根據美國疾病管制與預防中心（CDC）的報告，2018年美國醫院共進行了4,830萬例外科和非外科手術，其中許多手術需要進行血型鑑定，並且有可能進行輸血。人們對產前和新生兒護理的日益關注，包括母親和胎兒的血型匹配，正在推動市場成長。根據國家生命統計報告，2019年美國將有約375萬名新生兒，每個新生兒都可能需要對母親和嬰兒進行血型檢測。

新興國家缺乏基礎設施和先進血型技術成本高昂將如何阻礙血型檢測市場的成長？

特別是在新興國家，缺乏血型檢測基礎設施是一個重大障礙。根據2019年世界衛生組織（WHO）的報告，只有62%的國家有國家血液政策，中低收入國家的比例最低，為48%。現代血型測定設備和試劑價格昂貴，限制了它們的應用，特別是在資源匱乏的環境中。《輸血醫學》雜誌 2018 年發表的一項研究估計，在一個中型血庫中實施全自動血型分型系統的成本將在 10 萬至 50 萬美元之間，這可能會限制該系統的廣泛應用。

缺乏訓練有素的人員來操作先進的血型系統，阻礙了市場的成長。根據美國臨床病理學會2018年職缺調查顯示，美國血庫技術員/專家的空缺率為10.6%，顯示該領域的技能型專業人員嚴重短缺。手動方法仍然被廣泛使用，特別是在資源有限的環境中，但容易出現人為錯誤，從而限制信任和採用。《輸血》雜誌發表的 2020 年統合分析發現，手動血型分型的錯誤率為 0.05% 至 0.8%，取決於特定技術和環境。

The increase in voluntary blood donations has led to a higher demand for blood group recognition and cross-matching procedures for transfusion. Thus, the increase in voluntary blood donations surged the growth of market size surpassing USD 2.96 Billion in 2024 to reach the valuation of USD 6.16 Billion by 2031.

The increasing incidence of diseases like cancer, blood disorders, and chronic anemia is driving the need for blood transfusions and, consequently, blood typing. Thus, the rising prevalence of chronic diseases requiring blood transfusions enables the market to grow at aCAGR of 9.60% from 2024 to 2031.

Blood Group Typing Market: Definition/ Overview

Blood group typing is a vital medical procedure that determines a person's blood type by identifying specific antigens on the surface of red blood cells. This process is crucial in various medical applications, such as ensuring compatibility for blood transfusions and organ transplants, as well as managing pregnancies, to prevent hemolytic disease of the newborn, which occurs when the mother's immune system attacks the fetus's red blood cells.

The demand for accurate blood group typing continues to grow, driven by the increasing need for blood transfusions and organ transplantations. The World Health Organization (WHO) reports a significant rise in voluntary blood donations, with an increase of 10.7 million donations between 2008 and 2018, indicating a corresponding rise in blood typing procedures. This rise in demand is further fueled by the growing number of accidents, trauma, and injury cases worldwide. Research indicates that 6 out of 10 trauma-related deaths result from excessive bleeding within the first three hours, underscoring the importance of timely blood transfusions, which require accurate blood group typing.

Advancements in genetic testing and molecular diagnostics are enhancing the accuracy and speed of blood typing procedures, paving the way for more precise and tailored healthcare solutions. As healthcare systems prioritize patient safety and personalized treatment, the demand for reliable blood group typing is expected to rise, further expanding its medical and healthcare applications.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How the Technological Advancements in Blood Typing Methods Surge the Growth of Blood Group Typing Market?

Innovations in blood typing technologies, such as molecular typing and automated systems, are enhancing the efficiency and accuracy of blood group typing. A 2020 study published in the journal Transfusion Medicine Reviews found that the adoption of automated blood typing systems in blood banks increased by 35% between 2015 and 2019. Increased awareness among healthcare providers and patients about the critical nature of accurate blood typing is driving market growth. The Joint Commission, which accredits healthcare organizations in the U.S., reported in 2018 that the implementation of patient blood management programs, which include robust pre-transfusion testing, reduced blood product utilization by an average of 12% in participating hospitals.

The rising number of surgical procedures, many of which require blood transfusions, is boosting the demand for blood group typing. The Centers for Disease Control and Prevention (CDC) reported that in 2018, there were 48.3 million surgical and nonsurgical procedures performed in U.S. hospitals, with many requiring blood typing and potential transfusions. The growing focus on prenatal and neonatal care, including blood type compatibility testing between mother and fetus, is driving market growth. According to the National Vital Statistics Reports, there were approximately 3.75 million births in the United States in 2019, each potentially requiring blood typing for both mother and child.

How do the Lack Of Infrastructure in Emerging Countries and the High Cost Of Advanced Blood Typing Technologies Impede the Growth of the Blood Group Testing Market?

The lack of infrastructure for blood group typing, especially in emerging countries, is a significant restraint. According to a 2019 World Health Organization report, only 62% of countries had national blood policies, with lower-middle-income countries having the lowest rate at 48%. The expensive nature of modern blood typing equipment and reagents limits adoption, especially in resource-constrained settings. A 2018 study published in the journal Transfusion Medicine estimated that the cost of implementing a fully automated blood typing system in a medium-sized blood bank could range from $100,000 to $500,000, potentially limiting widespread adoption.

The lack of trained personnel to operate advanced blood typing systems hinders market growth. The American Society for Clinical Pathology's 2018 Vacancy Survey reported a vacancy rate of 10.6% for blood bank technologists/specialists in the United States, indicating a significant shortage of skilled professionals in the field. While manual methods are still widely used, especially in resource-limited settings, they are prone to human error, which can limit trust and adoption. A 2020 meta-analysis published in the journal Transfusion found that the error rate in manual blood typing ranged from 0.05% to 0.8%, depending on the specific technique and setting.

Category-Wise Acumens

How did the Increasing Chronic Disorders and Growing Number of Surgical Procedure Surge the Growth of the ABO Segment?

The ABO segment is dominant in the blood group testing market, driven by the rising prevalence of chronic diseases and the increasing number of surgical procedures requiring blood transfusions. Accurate ABO blood typing is crucial in ensuring compatibility between blood donors and recipients, significantly reducing the risk of adverse reactions during medical procedures. As a result, there has been a notable surge in demand for ABO blood typing tests, which is propelling the growth of this market segment.

Moreover, advancements in medical technology and diagnostic instruments have significantly enhanced the accuracy and efficiency of blood typing systems. The ability to swiftly and accurately determine blood types through automated methods has heightened the demand for ABO blood typing tests. Healthcare professionals prioritize patient safety and the reliability of medical procedures, making ABO testing an indispensable tool in modern healthcare. This growing emphasis on precision and efficiency ensures that the ABO segment will continue to dominate the blood group testing market in the years to come.

How the Extensive Use of Reagents & Kits in Blood Donation and Transfusion Procedure Surge the Growth of Reagents & Kits Segment?

The reagents & kits segment holds a dominant position in the blood group testing market, driven by their extensive use in blood donation and transfusion procedures. These products are essential for accurate blood typing, making them a critical component in ensuring compatibility between donors and recipients, particularly in life-saving situations such as surgeries, trauma care, and organ transplants. As the global demand for blood donations and transfusions continues to rise, the use of reagents & kits in healthcare facilities and blood banks has significantly increased, fueling the segment's growth.

The surge in voluntary blood donations and the expansion of healthcare infrastructure worldwide. With more individuals donating blood, the demand for reliable and efficient blood typing reagents has become paramount. Additionally, reagents are indispensable in determining blood types quickly and accurately, ensuring patient safety during transfusion procedures.

In addition, the segment is poised for continued growth as the adoption of advanced diagnostic technologies accelerates. As healthcare systems increasingly rely on automated and high-throughput instruments for blood typing, the need for specialized reagents & kits to complement these systems is expected to rise, ensuring the segment's strong presence in the market throughout the forecast period.

Country/Region-wise Acumens

How does the Significant Demand for Blood Transfusions Accelerate the Growth of the Blood Group Typing Market in North America?

North America substantially dominates the blood group testing market owing to the high demand for blood transfusions in North America, particularly in the United States. According to the American Red Cross, approximately 29,000 units of red blood cells are needed every day in the U.S. The organization also reports that nearly 16 million blood components are transfused each year in the United States.

The increased adoption of automated blood typing systems in North American healthcare facilities is driving market growth. A 2019 survey by the College of American Pathologists reported that 78% of participating laboratories in the U.S. and Canada were using fully or partially automated systems for ABO/Rh typing, up from 65% in 2014.

The favorable reimbursement policies for blood typing procedures and the rising number of regulatory approvals for advanced products are driving market growth in North America. The Centers for Medicare & Medicaid Services (CMS) reported that in 2020, the national average Medicare reimbursement for ABO and Rh blood typing (CPT code 86900) was $7.77, while for antibody screening (CPT code 86850) it was $17.28, providing financial incentives for healthcare providers to perform these tests. Additionally, the U.S. Food and Drug Administration (FDA) approved 12 new or updated blood typing-related products between 2018 and 2020, indicating a growing market for advanced blood typing technologies.

How the Rising Incidence of Chronic Diseases and Increasing Demand for Blood Transfusions Propel the Growth of Blood Group Testing Market in Asia Pacific?

Asia Pacific is anticipated to witness the fastest growth in the blood group testing market driven by the prevalence of chronic diseases like cancer and kidney disorders is growing in Asia Pacific countries, leading to a higher demand for blood transfusions and typing. According to the World Health Organization (WHO), the number of new cancer cases in the Asia-Pacific region is expected to increase from 8.8 million in 2018 to 11.5 million by 2025. This 30% increase will likely drive up the need for blood typing and transfusions.

Many Asia Pacific countries are investing heavily in healthcare infrastructure and increasing their healthcare spending, which supports the expansion of blood typing services. The Indian government's healthcare expenditure increased from 1.2% of GDP in 2013-14 to 1.8% in 2020-21, according to the Economic Survey 2020-21. This growth in healthcare spending is likely to boost investments in blood typing technologies and services.

There's an increasing awareness about the importance of blood donation in the region, supported by various government and non-government initiatives. In China, the number of voluntary blood donors increased from 12.32 million in 2011 to 15.48 million in 2019, according to data from the National Health Commission of China. This 25% increase in blood donors over eight years indicates a growing need for efficient blood typing services.

Competitive Landscape

The Blood Group Testing Market is a dynamic and competitive industry driven by factors such as increasing healthcare expenditure, growing awareness of blood group compatibility, and advancements in testing technologies. Several key players operate in this market, offering a range of products and services to meet the diverse needs of healthcare providers, blood banks, and individual consumers.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the blood group typing market include:

Abbott Laboratories
Bio-Rad Laboratories, Inc.
Hoffmann-La Roche Ltd.
Grifols, Immucor, Inc.
Ortho Clinical Diagnostics
Quotient Limited
BioMerieux SA
DiaSorin S.p.A.
Merck KGaA.

Latest Developments:

In June 2023, Quotient Limited announced the launch of its ALBA products in Sweden and the Netherlands. The items were also launched in France, Germany, Austria, Hungary, Italy, Greece, Poland, Romania, Luxembourg, and Slovakia.
In June 2023, Quotient Limited announced an agreement with Transmedic Pte Ltd to distribute ALBA by Quotient and MosaiQ in five Southeast Asian countries: Indonesia, Singapore, Malaysia, Thailand, and Vietnam.
In May 2023, Bio-Rad Laboratories, Inc. unveiled the IH-500TM NEXT System, a fully automated ID card system designed to address the changing demands and difficulties of the laboratory and healthcare environments.